Physician profile
Jeremy E Ensor
NPI 1780694125
$3,224.61
in general payments reported to CMS, 2019-2025
11 companies · $1,339 in 2025
The $1,339 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $698 · 2020: $189 · 2021: $107 · 2022: $127 · 2023: $369 · 2024: $396 · 2025: $1,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,104.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Visioneering Technologies, INC. | $919.08 | 2019-2025 | |
| Coopervision INC. | $680.93 | 2019-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Alcon Vision LLC | $544.13 | 2019-2025 | Total30, Precision7 |
| Bausch & Lomb Americas INC. | $192.30 | 2023-2025 | Infuse |
| Lkc Technologies, INC. | $184.06 | 2024 | |
| Abb Con-Cise Optical Group LLC | $131.64 | 2024 | Contact Lens, Spectacle Lenses |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $124.99 | 2019 | |
| Allergan, INC. | $124.55 | 2019 | |
| Glaukos Corporation | $124.35 | 2025 | Photrexa Viscous and Photrexa |
| Sun Pharmaceutical Industries INC. | $121.83 | 2025 | |
| Sight Sciences, INC. | $76.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremy Ensor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.